Prostate cancer is the most common malignancy diagnosed among men.Transrectal biopsy is a gold standard for detecting it. Patients undergoing this procedure are exposed to urinary tract infections leading even to sepsis. Treatment cost of prostate biopsy-related complications and insurance payouts is estimated at $1.7 bn in the USA and EU. DEBN delivers the optimal antibiotic combination directly to the prostate, precisely at the place where potential infections start reducing risk significantly
